Caroline Shiboski is Professor of Orofacial Sciences at the University of California, San Francisco. She obtained her DDS from the Université René Descartes in Paris, and has advanced training in Epidemiology (MPH and PhD from UC Berkeley) and Oral Medicine (she is a certified Diplomate of the American Board of Oral Medicine). Dr. Shiboski has been a faculty member in the UCSF School of Dentistry since 1994, after initially joining the school as a resident in the Advanced Education in General Dentistry program. She has been providing care to patients with oral mucosal diseases in the UCSF Sol Silverman Oral Medicine Clinic, and teaching Oral Medicine to pre-doctoral dental students and postgraduate residents for over 25 years.
Dr. Shiboski’s research focuses on the epidemiology of oral manifestations related to immune dysfunction and Sjögren’s disease (SjD), and has been funded through NIH grants and contracts consistently since 1994. She was part of the team that established the NIDCR-funded Sjögren’s International Collaborative Clinical Alliance (SICCA) in 2003, and has served as its Principal Investigator (PI) since 2010. SICCA Next Generation Studies (SICCA-NextGen), the largest biorepository and data registry for SjD in the world, is housed at UCSF and continues to yield important research aimed at identifying therapeutic targets for SjD.
Dr. Shiboski also led a team of international experts in the development and validation of the current classification criteria for SjD approved by the American College of Rheumatology and the European Alliance of Associations for Rheumatology in 2016. Dr Shiboski is the current contact PI for the Sjögren’s Team for Accelerating Medicines Partnership that is one of four disease teams participating in the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP®AIM) Program, a public-private partnership between NIH, industry, and non-profit organizations.
